Projects for undergraduate researches
[1] Characterization of the synergistic effect of combining PARP Inhibitor and BO-1978 in inhibiting the growth of small cell lung cancer cells, Yu-Hsiang Chen, 2023 - 2023
[2] Inhibition of STAT3 Reverses Cross-Resistance in Gemcitabine-Resistant Pancreatic Ductal Adenocarcinoma Cells, Ching-Wen Huang, 2023 - 2023
[9] Exploring drug synergy using PARP inhibitor and macropinocytosis inhibitor against PARPi-resistant ovarian cancer cells, Feng-Zhi Chen, 2022 -2023
[8]Characterizing the efficacy of PARP inhibitors in shRRM2 ovarian cancer cells, Min-Hsi Ku, 2022 – 2023
[7] Investigating novel RRM2 inhibitor Osalmid enhances therapeutic efficacy of PARP inhibitors in ovarian cancer cells, Ching Hua Pai, 2022 –2023
[9] Exploring the novel RRM2 inhibitor Osalmid coordinates the cGAS-STING innate immune pathway with PARP inhibitors in ovarian cancer cells, Zhen Yu Huang, 2022 – 2022
[10] Investigation of Inhibiting macropinocytosis in Ras-driven ovarian cancer, Yi-An Lin, 2022 – 2022
[11] Characteristic of BO-1978 against ovarian cancer cells, Wei-Lun Huang, 2021 – 2023
[12] Investigation of CACFD1 mediated metabolic changes in ovarian cancer cells, Yun-Chieh Wu, 2021 – 2023
[13] Characteristic of PARP inhibitor-resistant ovarian cancer cells, Tsai-Chieh Tseng, 2021 –
[14] Elucidation of macropinocytosis inhibition synergizes PARP inhibitor, Tam-Hong Leong, 2021 – 2022
[1] Characterization of the synergistic effect of combining PARP Inhibitor and BO-1978 in inhibiting the growth of small cell lung cancer cells, Yu-Hsiang Chen, 2023 - 2023
[2] Inhibition of STAT3 Reverses Cross-Resistance in Gemcitabine-Resistant Pancreatic Ductal Adenocarcinoma Cells, Ching-Wen Huang, 2023 - 2023
[9] Exploring drug synergy using PARP inhibitor and macropinocytosis inhibitor against PARPi-resistant ovarian cancer cells, Feng-Zhi Chen, 2022 -2023
[8]Characterizing the efficacy of PARP inhibitors in shRRM2 ovarian cancer cells, Min-Hsi Ku, 2022 – 2023
[7] Investigating novel RRM2 inhibitor Osalmid enhances therapeutic efficacy of PARP inhibitors in ovarian cancer cells, Ching Hua Pai, 2022 –2023
[9] Exploring the novel RRM2 inhibitor Osalmid coordinates the cGAS-STING innate immune pathway with PARP inhibitors in ovarian cancer cells, Zhen Yu Huang, 2022 – 2022
[10] Investigation of Inhibiting macropinocytosis in Ras-driven ovarian cancer, Yi-An Lin, 2022 – 2022
[11] Characteristic of BO-1978 against ovarian cancer cells, Wei-Lun Huang, 2021 – 2023
[12] Investigation of CACFD1 mediated metabolic changes in ovarian cancer cells, Yun-Chieh Wu, 2021 – 2023
[13] Characteristic of PARP inhibitor-resistant ovarian cancer cells, Tsai-Chieh Tseng, 2021 –
[14] Elucidation of macropinocytosis inhibition synergizes PARP inhibitor, Tam-Hong Leong, 2021 – 2022